Scancell
Scancell is a clinical-stage biotech developing active immunotherapies and antibody-based therapeutics for cancer.
Its pipeline spans DNA cancer vaccines, peptide immunotherapies and tumour-specific monoclonal antibodies targeting glycans expressed on cancer cells.
Lead programmes iSCIB1+ and Modi-1 are in Phase 2 trials for melanoma and solid tumours respectively. Two antibody assets have been licensed to Genmab.
The company is AIM-listed and was the first UK biotech to partner with the NHS Cancer Vaccine Launchpad.
Latest News
Scancell Wins MHRA Clearance for Phase III Melanoma Trial
Scancell has received UK clinical trial authorisation from the MHRA for its registrational Phase III trial of iSCIB1+ in advanced melanoma, following FDA clearance in January. The trial will enrol 550 stage III/IV melanoma patients across around 90 sites in the US, EU, UK, Canada and Australia, testing iSCIB1+ alongside ipilimumab and nivolumab against placebo plus the same combination, with progression-free survival as the primary endpoint and initial data expected in H2 2028.
Scancell Raises £15.7M to Fund Neuphoria Merger and Phase III Melanoma Trial
Scancell Holdings has raised £15.7 million in gross proceeds through a significantly oversubscribed UK placing and retail offer. The funds will support Scancell's merger with US biotech Neuphoria Therapeutics, creating a dual-listed group, and fund a global Phase III trial of its lead cancer immunotherapy for advanced melanoma, with primary results expected by late 2028.